报价延迟最少15分钟:2026/04/19 05:49 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.52 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.13/-4.85
|
|
企业价值
813.76M
|
| 资产负债 |
|
每股账面净值
10.51
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatmentof neuropsychiatric diseases, including schizophrenia. |
